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Abstract: Leukemia is the most common cancer in children, representing 30% of all childhood
cancers. The disease arises from recurrent genetic insults that block differentiation of hematopoietic
stem and/or progenitor cells (HSPCs) and drives uncontrolled proliferation and survival of the
differentiation-blocked clone. Pediatric leukemia is phenotypically and genetically heterogeneous
with an obscure etiology. The interaction between genetic factors and environmental agents represents
a potential etiological driver. Although information is limited, the principal toxic mechanisms
of potential leukemogenic agents (e.g., etoposide, benzene metabolites, bioflavonoids and some
pesticides) include topoisomerase II inhibition and/or excessive generation of free radicals, which
may induce DNA single- and double-strand breaks (DNA-DSBs) in early HSPCs. Chromosomal
rearrangements (duplications, deletions and translocations) may occur if these lesions are not properly
repaired. The initiating hit usually occurs in utero and commonly leads to the expression of oncogenic
fusion proteins. Subsequent cooperating hits define the disease latency and occur after birth and may
be of a genetic, epigenetic or immune nature (i.e., delayed infection-mediated immune deregulation).
Here, we review the available experimental and epidemiological evidence linking pesticide exposure
to infant and childhood leukemia and provide a mechanistic basis to support the association, focusing
on early initiating molecular events.
Keywords: infant and childhood leukemia; hematopoietic stem/progenitor cells; chromosomal
rearrangements; topoisomerase II; pesticides; DNA double-strand break; oxidative stress
1. Introduction
Leukemia is the most common childhood cancer, accounting for 30% of all cancers diagnosed
in children under 15 years of age, with an annual incidence of up to 40 cases per million children in
developed countries and an incidence peak between three and five years of age [1,2]. Pediatric acute
leukemia is a phenotypically- and genetically-heterogeneous disease of immature hematopoietic stem
and progenitor cells (HSPCs). Phenotypically, it can target B-cell progenitors (B-cell acute lymphoblastic
leukemia (B-ALL)), T-cell progenitors (T-ALL) or myeloid progenitors (acute myeloid leukemia (AML)).
Acute leukemia can be further stratified according to the differentiation stage at which HSPCs are
blocked; for example, B-ALL can have a pro-B (proB-ALL) or pre-B phenotype (preB-ALL) [3]. Similarly,
AML can affect both immature (subtype M0 of the French-American-British classification of AML)
and mature lineage-committed types, such as erythroblastic or megakaryoblastic leukemia (subtypes
M6 and M7, respectively). Seventy percent of pediatric acute leukemias are ALL and 30% are AML.
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Genetically, ALL and AML can be further stratified according to molecular cytogenetics [4,5], which
represents a prognostic factor.
Fetal hematopoiesis begins in the aorta gonad-mesonephros region to subsequently colonize the
fetal liver (FL) and ultimately, just before birth, the bone marrow [6]. FL hematopoiesis entails an
active proliferation of progenitors, rendering fetal HSPCs susceptible to oncogenic transformation
through DNA damage mediated by chemical exposure during pregnancy [7]. Although the etiology
of ALL remains elusive, ionizing radiation, congenital genetic syndromes and in utero exposure to
specific genotoxic chemicals, including household pesticides, represent prime etiological suspects [8].
Importantly, altered patterns of infection during early childhood might also contribute to acute
leukemia in children [9–11].
We here review the available experimental and epidemiological evidence linking pesticide
exposure with infant and childhood leukemia and provide a mechanistic basis to support the
association, focusing on early molecular events. However, the paucity of mechanistic data is a
major obstacle to fully understanding the toxicological pathways involved. Causation pathways are
likely to be multifactorial, and it is possible that the risk of pediatric leukemia from environmental
exposure is influenced by genetic susceptibility.
2. Evidence Linking Pesticide Exposure with Pediatric Leukemia
2.1. Epidemiological Studies Supporting the Association
There is a growing concern about whether chronic low-level pesticide exposure during pregnancy
or childhood increases the risk of childhood leukemia. Epidemiological studies suggest that pesticide
exposure may have a greater impact on children than adults [12,13]. Almost all of the available
evidence has focused on pediatric leukemia without making a distinction between infant and childhood
leukemia, which are etiologically and pathologically different entities. However, most epidemiological
studies are limited because no specific pesticides have been directly associated with the risk of
leukemia, but rather the broad term “pesticide exposure” [13,14]. Such associations are mainly based
on subjects’ recall of the pesticide exposure, which hampers the drawing of conclusions because of
recall/information bias.
In contrast to childhood leukemia, very few studies have examined the risk of infant leukemia and
pesticide exposure. An international collaborative study on transplacental chemical exposure and risk
of infant leukemia found an increased risk after in utero exposure to household pesticides (propoxur
and other methylcarbamate insecticides), the therapeutic analgesic dipyrone and hormonal intake
(estrogens). In these cases, infant leukemia was associated with the mixed lineage leukemia (MLL)
gene fusion, likely as a result of topoisomerase II inhibition [15,16]. Although the aforementioned
study was based on a rather small sample size, an increased risk (Odds Ratio—OR: 2.18) of infant
leukemia was shown in mothers exposed to domestic insecticides during pregnancy. Since estrogens
can be metabolized to catechol estrogen-3,4-quinones [17], the association found for infant leukemia
might be due to topoisomerase II inhibition caused by quinone metabolites generated during estrogen
metabolism [7]. A further Brazilian study found that over use of pesticides during pregnancy was
associated with ALL and AML (OR: 2.10 and 5.01, respectively) in children <1 year of age [18].
Moreover, maternal exposure to the insecticide permethrin (assessed by self-reporting) was associated
with a higher risk of leukemia in children <1 year of age, with an OR of 2.47 for ALL and 7.28 for
AML. This finding was also supported by a case-control study in China where the use of pyrethroids
(assessed by urine levels of major metabolites) was associated with a greater risk of ALL [19].
The presence of the herbicide chlorthal in household dust samples was also associated with an
increased risk of ALL in children <8 years, with a significant dose-response trend [20]. The association
was greater with the herbicide mixture chlorthal plus alachlor. Other studies, however, report no
significant associations. For example, no significant risk of childhood leukemia was found with
exposure to some agricultural and residential herbicides, such as metolachlor, bromoxynil, cyanazine
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and 2,4-dichlorophenoxyacetic acid [20,21]. Furthermore, a case-control study on leukemia in children
<1 year old from the American Children’s Oncology Group failed to find a significant association
between household exposure to insecticides or rodenticides and ALL or AML [22].
Different meta-analyses have consistently shown an increased risk of childhood leukemia
associated with pesticide exposure [13,23]. However, this review will focus on the latest
quantitative synthesis of evidence from studies. A recent meta-analysis has shown that maternal
occupational pesticide exposure during pregnancy and/or paternal occupational pesticide exposure
near-to-conception increases the risk of leukemia in offspring [24]. The authors pooled data from 13
case-control studies participating in the Childhood Leukemia International Consortium (CLIC) and
found an almost two-fold increased risk of AML in mothers exposed to pesticides during pregnancy,
whereas no significant risk was found for paternal exposure around conception. In relation to ALL, the
same study observed a 20% increased risk with paternal exposure around conception, which appeared
to be more evident for pediatric T-cell ALL. By contrast, no significant association was found between
maternal exposure during pregnancy and risk of B or T-cell ALL. In a separate study investigating
residential pesticide exposure, Bailey et al. [25] pooled data from 12 case-control studies in the CLIC
and found a significant increased risk of ALL associated with exposure to any pesticide shortly before
conception, during pregnancy and after birth (OR: 1.39, 1.43 and 1.36, respectively). Little variation
was observed with the type of pesticide. Regarding AML, an increased risk was found for exposure
to any pesticide in the few months prior to conception and during pregnancy (OR: 1.49 and 1.55,
respectively); however, exposure after birth failed to demonstrate an increased leukemogenic risk.
A recent meta-analysis conducted by Chen et al. [12] pooled 16 case-control studies and found that
childhood exposure to indoor, but not outdoor, residential insecticides was associated with an increased
risk of pediatric leukemia (OR: 1.47). A slightly weaker association was found for herbicide exposure
(OR: 1.26). Notwithstanding these positive associations, observational studies on pesticide exposure
and pediatric leukemia have a number of weaknesses to claim causal relationships. The consistency
of findings across meta-analyses may be due to the considerable overlap in the studies included in
the different meta-analyses undertaken. Many epidemiological analyses have not been performed
using methodologically-rigorous association studies. Limitations include the lack of an accurate
exposure estimate (from both a qualitative and quantitative standpoint), lack of temporal concordance
(most studies were case-control in design) and little information on the dose-response relationship.
In addition, the available epidemiological evidence may be challenged by endogenous or exogenous
factors, such as genetic susceptibility, lifestyle and co-exposure to other environmental agents.
2.2. In Vitro Studies
The few in vitro studies available so far have shown that captan and captafol (two related
chloroalkylthiocarboximide fungicides) decrease the activity of topoisomerase II by 50% and 20%,
respectively, at a concentration of 1 µM [26]. Similarly, thiram (a dithiocarbamate fungicide) inhibits
topoisomerase II at 10 µM [27]. However, genotoxic potential (i.e., genetic abnormalities, mutations) of
these fungicides occurred only at very high doses (10–100 mM) in vivo using common fruit flies [26].
More recently, the organophosphate (OP) insecticide chlorpyrifos has been reported to induce DNA
double-strand breaks (DSBs) and MLL gene rearrangements in human fetal liver CD34+ HSPCs as a
consequence of topoisomerase II inhibition [14].
Other OP pesticides have been implicated in leukemogenesis, particularly isofenphos, diazinon
and fenitrothion. An in vitro study using the human leukemic cell line K562 demonstrated metabolic
changes consistent with a leukemogenic potential of isofenphos [28]. In addition, human peripheral
blood lymphocytes exposed to isofenphos exhibited dose-dependent damage to chromosomal DNA,
as well as disruption of the cholinergic nuclear signaling pathway, which collectively could lead to
genomic instability and leukemogenesis [29]. In an in vitro study using diazinon, a concentration
of 0.1 µM induced hypermethylation of several genes involved in cell cycle arrest, such as
cyclin-dependent kinase inhibitor 1A (CDKN1A) and 1C (CDKN1C), and tumor suppressor genes, such
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as p53 and PTEN [30]. Fenitrothion at low concentrations (1 µM) also induced chromosomal damage
in the B-cell leukemia/lymphoma-2 cell line BCL-2 [31].
3. Gene-Environment Interactions
For most pediatric leukemias, multiple genetic polymorphisms of xenobiotic metabolizing
enzymes may interact with environmental, dietary and maternal factors to modulate the development
of the disease. For example, quinones, which are capable of inhibiting topoisomerase II and can cleave
the MLL gene at topoisomerase II cleavage sites, may be poorly detoxified depending on the activity of
NAD(P)H:quinone oxidoreductase 1 (NQO1), an enzyme that detoxifies chemicals with quinone rings,
such as bioflavonoids and benzene metabolites. Thus, genetic polymorphisms of NQO1 resulting in
low-activity variants might be associated with an increased risk of infant leukemia. By contrast, in
childhood ALL without MLL rearrangements, deficiency of the NQO1 gene is not associated with the
etiology of the disease [32].
Global DNA hypomethylation is associated with activation of oncogenes and neoplastic
processes [33], whereas the hypermethylation of 51 cytosine-phospho-guanine (CpG) islands in
promoter regions of some tumor suppressor genes prevents their transcription and promotes the
development of tumors [34]. The genetic regulation of folate metabolism may have an influence on the
preleukemic clone origin via DNA hypomethylation of key regulatory genes, rendering the genome
vulnerable to genomic instability [35]. The presence of some polymorphisms in genes involved in folate
metabolism reduces enzyme activity, leading to inadequate folate levels and DNA hypomethylation,
ultimately contributing to the neoplastic process [35,36]. The insufficient input of folate increases the
plasma concentration of homocysteine and S-adenosylhomocysteine, with the latter being a general
inhibitor of adenosylmethionine-dependent methyltransferases [37]. Inhibition of these enzymes may
alter both DNA methylation and transcriptional regulation [36,38]. The 677C>T gene polymorphism
in methylenetetrahydrofolate reductase (MTHFR) has been linked to a decreased risk of childhood
ALL, likely as a result of higher production of 5,10-MTHF and thymidine, which improve the fidelity
of DNA synthesis and repair [39]. On the other hand, inactivating polymorphisms of detoxifying
enzymes involved in carcinogen metabolism, such as glutathione S-transferases (GST), in parents have
been associated with the development of ALL in their children <1 year old. The deletion of both the
GSTT1 and GSTM1 genes in either parent might affect the risk of infant leukemia [40]. Furthermore,
genetic polymorphisms of xenobiotic transport and metabolism pathways are associated with the
risk of childhood ALL. In particular, polymorphisms of the ABCB1 gene, which encodes a membrane
transporter of lipophilic compounds, may interact with household insecticide exposures to increase the
risk of disease [41]. Genetic variability in DNA repair pathways and cell cycle checkpoints might also
interact with environmental, dietary, maternal and other external factors affecting the development
of ALL. In summary, the limited data available suggest that dietary and environmental exposure to
substances targeting topoisomerases together with the reduced ability of fetuses or their mothers to
detoxify such compounds because of polymorphic variants of given genes could contribute to the
development of pediatric leukemia [8,42].
The International Childhood Acute Lymphoblastic Leukemia Genetics Consortium revealed
limitations in current studies on genetic susceptibility and the risk of ALL because of difficulties in
conducting statistically- and methodologically-rigorous investigations [43]. Genome-wide association
studies of childhood ALL have provided robust evidence for four low-penetrance susceptibility
variants, which confer only a modest increase in risk. Moreover, the well-recognized ethnic differences
in the risk of ALL represent a weakness in assessing the interplay between inherited and non-genetic
risk factors. Given the small frequency of many ALL subgroups, the identification of differential effects
will realistically be possible only through multi-center pooled analyses [43].
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4. Early Molecular Events Involved in Pesticide-Associated Pediatric Leukemogenesis
Despite the rather comprehensive epidemiologic evidence linking pesticide exposure during
different reproductive stages (pre-conception, pregnancy and early postnatal life) and pediatric
leukemia, robust underlying pathological mechanisms remain unknown. The initiating event at
the molecular level might be the induction of chromosomal rearrangements as a result of pesticide
exposure and subsequent topoisomerase II inhibition or generation of oxidative stress, leading directly
or indirectly to DNA damage. A mechanistic explanation follows.
4.1. DNA Double-Strand Breaks (DSBs)
Under some circumstances, oxidative lesions can lead to DNA DSBs formation in HSPCs.
Environmental exposures to numerous chemicals, including many pesticides, have been shown in vivo
and in vitro to generate oxidative species that can ultimately induce DNA base or sugar oxidative
damage, leading to single-strand breaks (SSBs) and DSBs formation in the DNA [44]. For example,
OP insecticides (chlorpyrifos, methyl-parathion, malathion), methyl-carbamates (methomyl) and the
herbicide paraquat all cause oxidative DNA damage followed by DNA SSBs and DSBs [45–48]. There is
also evidence of pesticide-induced oxidative stress and DNA damage in agricultural workers [47].
Additionally, oxidative species may interact with biological molecules to disrupt normal DNA synthesis
and repair, and so, inhibition/inactivation of antioxidant proteins or DNA repair enzymes may also
be an underlying molecular mechanism [49]. Along this line, pesticides can disrupt a number of
antioxidant enzymes, including superoxide dismutase and catalase [50], rendering oxidative stress [51].
DSBs can arise under different circumstances: (i) when two SSBs form close to each other on
opposite strands; (ii) upon enzymatic DNA cleavage next to an SSB on the opposite strand; or (iii) when
either DNA replication or transcription takes place at sites of misrepaired DNA. DSBs constitute the
first molecular event in the generation of chromosomal aberrations [52]. For instance, chlorpyrifos is
reported to cause DNA DSBs and further chromosomal rearrangements (i.e., MLL) through oxidative
stress in human FL HSPCs [53]. However, chlorpyrifos can also induce DNA DSBs as a result of
topoisomerase II inhibition in FL HSPCs in a manner similar to that produced by etoposide [14].
Analogously, blood lymphocytes from pesticide sprayers have greater fragile site breakage than
normal individuals following treatment with aphidicolin, an inhibitor of DNA polymerases [54].
Chromosomal fragile sites are regions of the genome prone to breakage following exposure to many
chemicals, including environmental and chemotherapeutic agents. During DNA replication, fragile
site-inducing conditions can uncouple the helicase complex from the DNA polymerase, resulting in
long stretches of single-stranded DNA and further DNA breakage [55]. Aphidicolin can also induce
fragile site breakage through a topoisomerase II-mediated mechanism [56].
Topoisomerase II has critical functions in both DNA replication and transcription processes, and
the so-called “topoisomerase II poisons” disrupt the DNA-induced topoisomerase II cleavage-religation
equilibrium through the stabilization of ternary (drug-DNA-enzyme) complexes, termed cleavage
complexes [57]. Chemical-induced breakpoints are strongly associated with predicted topoisomerase II
cleavage sites (i.e., MLL), thus supporting a role for topoisomerase II-mediated breakage upon exposure
to environmental agents. The high frequency of topoisomerase II recognition sites in specific DNA
regions and the high expression of this enzyme in human CD34+ HSPCs represent favorable conditions
for breakage following exposure to agents targeting topoisomerase II activity (i.e., bioflavonoids and
quinones). Because CD34+ HSPCs appear to be more sensitive to DNA damage than committed
progenitor cells, exposure to low levels of different chemicals may induce DNA breakage at certain
sites in HSPCs, increasing the risk of chromosomal rearrangements. If affected cells survive, they
continue growing and dividing, thus perpetuating DNA lesions and starting the chain of events that
will eventually lead to leukemogenesis [55].
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4.2. Chromosomal Translocations
Key molecular events leading to pediatric leukemia pathogenesis are chromosomal translocations.
These generally result from the exchange of chromosomal arms between heterologous chromosomes,
and DNA DSBs are prerequisites for their occurrence. Chromosomal translocations ultimately result
in the deregulation of key cellular proteins, especially those encoded by proto-oncogenes and tumor
suppressor genes, which are critical functional regulators of the cell [58]. Two functional classes of
translocations are known. The first one relocates a proto-oncogene (or genes encoding for non-antigen
receptors or transcription factors) into regulatory regions of actively-transcribed genes (such as those
encoding for immunoglobulin chains or T-cell receptors), causing dysregulated expression of an intact
protein. The second class of translocations juxtaposes two genes to encode a chimeric protein, which is
functionally distinct from the wild-type proteins [1].
Although the mechanistic generation of chromosomal translocations is not well understood, they
may arise from improper DNA repair or erroneous recombination of variable (V), diversity (D) and
joining (J) gene segments (a process known as V(D)J recombination). As for improper DNA repair,
reactive oxygen species (ROS)-induced DSBs in human FL CD34+ HSPCs following maternal exposure
to chemicals triggers recombination/repair pathways by non-homologous end-joining (NHEJ) [14].
The majority of damaged HSPCs may either successfully repair the DNA DSBs or fail to do so and
undergo apoptotic cell death. In a fraction of cells, the repair of the DNA DSBs within particular
breakpoint cluster regions (bcr) is not completed correctly, giving rise to chromosomal translocations or
deletions [59]. For fusion genes to be leukemogenic, DSBs must occur simultaneously in two chromosomes
and must also involve the coding region of the genes to generate an exon-exon in-frame functional chimeric
gene product. Importantly, this has to occur in an HSPC that has managed to bypass cell death and
displays a sustainable lifespan and clonal potential to propagate the chimeric gene product [60].
Erroneous V(D)J recombination usually occurs in developing lymphocytes during cell maturation,
where V(D)J gene segments of immunoglobulin chains or T-cell receptors are rearranged to yield a wide
range of immunoglobulins and T-cell receptors. The process entails the cleavage of the V(D)J gene at the
flanking recombination signal sequences (RSS) by lymphocyte-specific recombination-activating gene
(RAG) endonucleases and subsequent ligation of the segments via the classical NHEJ pathway [61].
In pediatric leukemia, chromosomal translocations and deletions often arise as a result of mistakes in
V(D)J rearrangements because RAG enzymes can erroneously recognize and target RSS-like sequences.
V(D)J-recombinase-mediated rearrangements may occur at both immune RSS and non-immune
cryptic RSS (cRSS), which are widely distributed throughout the genome [62]. There is growing
evidence that in vivo exposure to DNA-damaging agents, including pesticides, can increase the
frequency and alter the recombination site distribution of V(D)J rearrangements at cRSS [63,64].
An increase in V(D)J-recombinase-mediated events at either immune or non-immune RSS following
exposure to DNA-damaging agents could play an important role in environmentally-induced genetic
alterations associated with leukemia development. Nonetheless, the mechanism by which exposure
to DNA-damaging agents could increase the frequency of V(D)J-recombinase-mediated genomic
rearrangements remains unclear [64].
5. Pathobiology of Pediatric Leukemias
Given the distinct natural history and pathogenesis of infant and childhood leukemia, both
entities will be addressed separately, although a chromosomal translocation is frequently the common
initiating oncogenic event in both entities.
5.1. Infant Leukemia
Infant acute leukemia shows unique clinical and biological features and is commonly associated
with rearrangements in the MLL gene (MLL-r), a master gene located on chromosome 11q23 that
regulates normal human hematopoietic development and differentiation [65]. The MLL gene encodes a
Int. J. Mol. Sci. 2016, 17, 461 7 of 16
methyltransferase with activity for lysine 4 of histone H3 (H3K4), which mediates changes in chromatin
associated with epigenetic transcriptional activation that plays an essential role in regulating gene
expression during early development and hematopoiesis [66]. Rearrangements involving the MLL
gene have been reported to occur only in mice with defects in DNA damage response and not in
wild-type animals [67]. MLL-r functions as the initiating, and perhaps the sole driving, oncogenic
event by dysregulating epigenetic and/or transcriptional programs [33] (Figure 1). Epidemiological
and genetic studies have suggested that MLL-r may result from transplacental exposure to DNA
topoisomerase-II inhibitors during gestation, such as chemotherapeutic agents, benzene metabolites
(i.e., benzoquinone), quinolone antibiotics, bioflavonoids present in some fruits and vegetables and
some pesticides [7,33,68]. However, exposure to topoisomerase-II inhibitors is not sufficient per se for
rearrangement of MLL, and the genetic background, such as mutations in the DNA damage response
pathway, may influence the likelihood of MLL-r [67].
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Figure 1. Chain of pathogenic events linking pesticide exposure to the development of infant
MLL-rearranged acute leukemia.
The existence of rec bination-prone sequences in the MLL bcr region supports he contention
that ML -r results from DNA breakage and recombination events. The genomic instability within
MLL bcr may be the consequence of increased ROS generation [69]. The MLL fusion gene renders
HSPCs more vulnerable to DNA repair and cell-cycle deregulation, facilitating the rapid acquisition of
additional, secondary genetic changes, particularly upon continued exposure to genotoxic chemicals
in utero [7,70]. These chemicals target early mesodermal precursors or HSPCs residing mainly in
the FL wher they inhibit t poisomerase-II acti ity and produce DNA DSB within the MLL bcr,
which are not roperly repaired by ho ologous rec bination or NHEJ. Because those mesodermal
precursors or HSPCs are rapidly dividing and have high topoisomerase II content, they may be particularly
sensitive to damage by topoisomerase II-targeting chemicals during a critical developmental window of
vulnerability [33,71–75]. However, because of the very short latency of infant leukemia, it remains obscure
whether the fusion gene generated from chromosomal translocations requires additional cooperating
oncogenic hits for leukemogenesis. Although recurrent activating mutations of genes associated with
cellular prolif ration, such as omp nents of the RAS signaling pathway, have bee reported [76–79],
function l studi revealed that these mutations are impo tant for tumor maintenance rather than initiation
in human HSPCs [80]. MLL breakage itself is not sufficient for the development of full-blown infant
leukemia, even if the DNA damage response is defective. Activation of cellular proliferation by mutation
of other genes might be necessary for overt leukemia [67]. The transformation mediated by the aberrant
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proteins encoded by fusion genes might depend on alternative (epi)-genetic cooperating lesions at a critical
developmentally-earlier window of stem cell vulnerability to develop overt leukemia [33].
Intriguingly, and in contrast to the global dogma of cancer biology, MLL-r infant leukemia
has been shown to have abnormal hypermethylation in non-enhancer, non-promoter regions,
perhaps contributing to genomic stability and a silenced mutational landscape [76,81,82]. Extensive
hypermethylation of tumor suppressor genes resulting in gene silencing has been observed in some
cases of MLL-r infant leukemia [83].
5.2. Childhood Leukemia
Childhood leukemia has a prevalence peak at ~3–5 years of age, suggesting that environmental
exposures in utero or during early childhood might be risk factors [25]. Under the current paradigm,
the first initiating oncogenic mutation usually involves structural or numerical chromosomal
alterations, impairing normal cell differentiation, while secondary hits more commonly comprise
mutations affecting developmentally-regulated master transcription factors or membrane-proximal
signaling pathways conferring proliferation and survival advantages to the differentiation-blocked
clone [1,7,8,84,85]. The development of leukemia requires the activation of cell proliferation in addition
to differentiation blockage [67]. Numerical aberrations (i.e., hyperdiploidy) are also common hallmarks
in childhood B-cell ALL.
The most common chromosomal aberrations are E2A-PBX1, TEL-AML1 and MLL-r for B-ALL
and AML1-ETO and MLL-r for AML. Similar to MLL rearrangements, the resulting aberrant
chimeric proteins alter the normal transcriptional program and block normal B-cell and/or myeloid
differentiation [8,86–88] (Figure 2). Although the AML1 gene has been linked to anti-topoisomerase
II agents, similar to the MLL gene, TEL-AML1 is not sufficient to cause the disease by itself. As this
fusion gene is observed in cord blood from about 1% of normal newborns, a significant proportion
of the population carries self-limiting preleukemic clones, and the majority of them do not result
in disease [3]. The longer latency observed in childhood leukemia unequivocally indicates that the
initiating chromosomal translocation itself is unlikely to convert a preleukemic clone into an overt
disease, thus suggesting the need for secondary cooperating (epi)-genetic events.
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disease, thus suggesting the need for secondary cooperating (epi)-genetic events. 
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Figure 2. Chain of pathogenic events linking pesticide exposure to the development of childhood
leukemia. Blue arrows indicate events related to the “first hit” and red arrows events related to the
“second hit” (for more details, see Section 5.2).
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Dysfunction of the immune system and delayed infections have been linked to childhood
leukemia [9,89]. Two distinct underlying mechanisms might explain this association: (i) a lower
repertoire of infections during early immune development; and (ii) an altered congenital responder
status to infection resulting in functionally-aberrant clinical presentation of occasional infections.
Thus, an untimely and excessive inflammatory response abolishes normal hematopoiesis, promoting
selective expansion of a preleukemic clone (Figure 2) because of proliferative advantage and increased
likelihood for a second mutation required for the development of the disease to occur [33]. In turn,
early childhood infections or vaccination may reduce the likelihood of leukemia [90]. Importantly,
the major histocompatibility genes might play a role in the linkage between patterns of infection
and leukemia risk, as several HLA haplotypes have been associated with childhood leukemia [3].
However, other studies have suggested that major histocompatibility complex-defined variation in
immune-mediated response is unlikely to be a major risk factor [91].
Aberrant RAG activity resulting in genomic rearrangements may be a crucial secondary
mechanism leading to B-cell ALL. Aberrant RAG activities can result in various oligoclonal V(D)J
recombination events and the inactivation of genes required for B-lineage differentiation [87]. A clear
link between RAG and childhood leukemia through inflammatory mechanisms has been recently
reported [89], further connecting immune system-RAG-childhood leukemia.
6. Role of Acetylcholinesterase in Leukemogenesis
Moderate acetylcholine (ACh) levels are crucial for controlling immune and inflammatory
functions in peripheral tissues. An increase in ACh above a certain threshold can suppress the
production of pro-inflammatory cytokines. Acetylcholinesterase (AChE) contributes to regulating ACh
levels and, thus, modulates inflammation [92]. In particular, ACh produced by the vagus nerve and/or
by peripheral leukocytes [93] can potently modulate several classical immune reactions by activating
the α7-nicotinic ACh receptor on the leukocyte membrane, which in turn blocks the nuclear factor
kappa B (NF-κB)-mediated production of pro-inflammatory cytokines, such as IL1β and tumor necrosis
factor alpha [92]. Because mesenchymal stromal/stem cells carry both nicotinic and muscarinic ACh
receptors [94], niche-derived cholinergic signals may play a role in hematopoiesis by regulating
proliferation and apoptosis of HSPCs undergoing erythroid and myeloid differentiation [95].
The ACHE gene includes multiple putative binding sites for hematopoietic transcription factors.
Alternative splicing gives rise to “synaptic” (AChE-S) multimers, which control ACh levels in the
brain and muscles, “erythrocyte” (AChE-E) dimers and stress-induced “read-through” (AChE-R)
monomers [96]. AChE-R is involved in cell proliferation, whereas AChE-S can be induced during
apoptosis [97]. Under stress responses, blood AChE-R undergoes C-terminal cleavage rendering a
C-terminal peptide (ARP) of 55 kDa, which promotes the myeloproliferation and thrombopoiesis
characteristics of cellular stress [98]. Because ARP functions as a hemopoietic growth factor promoting
proliferation of CD34+ HSPCs, circulating AChE-R and/or ARP might be involved in directing CD34+
HSPCs towards prolonged granulocytosis [96]. Furthermore, ACHE has been reported to play a role
in hematopoiesis by regulating proliferation, differentiation and apoptosis of erythroid and myeloid
progenitors. This might explain, at least in part, the association of perturbations in ACHE gene
expression with myeloid leukemia [99], particularly after exposure to anticholinesterase insecticides,
such as OPs.
ACHE is located on chromosome 7q22 within a critical region subject to non-random chromosomal
abnormalities. The remarkable abundance of SINEs (short interspersed elements), in particular Alu
repeats, in the ACHE locus implies exceptional susceptibility to retrotransposition events, which are
assisted by the existence of chromosomal breakages. Alu repeats also facilitate unequal crossing-over,
altogether contributing to the instability of this region. Chromosomal rearrangements could result in
the loss of upstream transcription factor binding sites and, thus, may affect ACHE gene expression
under stress or exposure to anti-AChE agents. This explains the reported chromosomal aberrations
involving 7q22 in leukemic patients [100]. The proximal promoter of the ACHE gene contains consensus
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motifs for the leukemia-associated factor AML1/Runx1 and c-fos, a transcription factor known to
regulate ACHE gene expression under stress [101]. Hence, the loss of DNA on chromosome 7 may
play a significant role in AML [95–102]. Furthermore, a study of 1880 children with ALL reported that
4% of them had DNA losses involving chromosome 7 [103].
A pivotal role of AChE has been suggested in apoptosis. While the 55-kDa AChE protein is
selectively induced during apoptosis, its suppression inhibits apoptosome formation and rescues
cells from apoptosis [104]. The 55-kDa AChE protein is negatively regulated by the activation of the
phosphatidylinositol-3 kinase (PI3K)/protein kinase B (Akt) pathway [104,105]. This signaling cascade
is crucial to cell cycle progression, transcription, translation, differentiation, apoptosis, motility and
metabolism [106]. The decrease in AChE activity and the consequent increased level of ACh could
cause cholinergic overstimulation and enhance cell proliferation in lung cancer [97]; however, whether
a similar effect can occur in leukemogenesis is unknown. On the other hand, AChE can hydrolyze
lipid peroxides, raising the possibility that a reduction in enzyme activity increases oxidative stress
and cellular damage [97].
7. Conclusions
Overall, there is sustained epidemiological evidence to suggest a risk of pediatric leukemia upon
exposure (in utero and/or after birth) to some classes of pesticides, but scientific/mechanistic studies
to definitively support this association are lacking. Pesticides may induce topoisomerase II inhibition
or generation of oxidative stress, consistently leading to misrepaired DNA cleavage and further
chromosomal aberrations in HSPCs. This early molecular event might be sufficient for triggering
infant leukemia, but not childhood leukemia, which requires further postnatal events for overt disease.
The combination of epidemiological and case-based genomic studies together with cell biology analyses
would be useful to elucidate the etiology of pediatric leukemia. In particular, this approach would
help to better understand the biological and genetic evidence that is pertinent to the mechanisms by
which pesticides might impact on the risk of pediatric leukemia.
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